{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:22:12Z","timestamp":1790490132186,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"978","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A paraprotein is a monoclonal immunoglobulin or light chain present in the blood or urine; it is produced by a clonal population of mature B cells, most commonly plasma cells. In individuals aged &amp;gt;50 years the incidence of a paraprotein is 3.2%. Plasma cell disorders can be considered as a spectrum of conditions ranging from monoclonal gammopathy of undetermined significance (MGUS), through asymptomatic, to symptomatic myeloma. MGUS is defined by a low level of paraprotein &amp;lt;30 g\/l, bone marrow plasma cells &amp;lt;10% and the absence of myeloma related organ or tissue damage (predominantly renal, skeletal or bone marrow impairment.) MGUS requires no therapy and the overall risk of progression to myeloma is 1% per year. Myeloma remains incurable with a median survival of 3\u20134 years; autologous stem cell transplant can prolong survival, if appropriate. Thalidomide in combination with dexamethasone has an emerging role in the treatment of myeloma.<\/jats:p>","DOI":"10.1136\/pgmj.2006.054627","type":"journal-article","created":{"date-parts":[[2007,4,2]],"date-time":"2007-04-02T17:58:50Z","timestamp":1175536730000},"page":"217-223","source":"Crossref","is-referenced-by-count":37,"title":["Management of paraproteinaemia"],"prefix":"10.1093","volume":"83","author":[{"given":"Lucy","family":"Cook","sequence":"first","affiliation":[{"name":"Department of Haematology, Imperial College , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald H C","family":"Macdonald","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,4,2]]},"reference":[{"key":"2023042013000479400_bib1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2023042013000479400_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"2023042013000479400_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance","volume":"134","author":"Kyle","year":"2006","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2141.2004.04898.x","article-title":"Guidelines on the diagnosis and management of chronic lymphocytic leukaemia","volume":"125","author":"Oscier","year":"2004","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib5","author":"Jaffe","year":"2001"},{"key":"2023042013000479400_bib6","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"2023042013000479400_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1297-319X(01)00343-8","article-title":"Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review","volume":"69","author":"Lamboley","year":"2002","journal-title":"Joint Bone Spine"},{"key":"2023042013000479400_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199805283382207","article-title":"Neuropathies associated with paraproteinemia","volume":"338","author":"Ropper","year":"1998","journal-title":"N Engl J Med"},{"key":"2023042013000479400_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"2023042013000479400_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.1992.tb08245.x","article-title":"Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance","volume":"81","author":"Blade","year":"1992","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"2023042013000479400_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05045.x","article-title":"Serum free light chains for monitoring multiple myeloma","volume":"126","author":"Mead","year":"2004","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"2023042013000479400_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1992.tb06400.x","article-title":"Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western Sweden","volume":"80","author":"Hjorth","year":"1992","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"2023042013000479400_bib17","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma","author":"Djulbegovic","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"2023042013000479400_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"2023042013000479400_bib20","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"2023042013000479400_bib21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"key":"2023042013000479400_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.2004.04970.x","volume":"125","author":"Guidelines Working Group of UK Myeloma Forum, British Committee for Standards in Haematology, British Society for Haematology Guidelines on the diagnosis and management of AL amyloidosis","year":"2004","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"2023042013000479400_bib24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2141.2004.04834.x","article-title":"Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma","volume":"124","author":"Soutar","year":"2004","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1365-2141.1996.d01-1852.x","article-title":"A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma","volume":"94","author":"Abrahamson","year":"1996","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-2141.1997.d01-2122.x","article-title":"A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma","volume":"97","author":"Raje","year":"1997","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","article-title":"Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2023042013000479400_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"2023042013000479400_bib29","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"2023042013000479400_bib30","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"key":"2023042013000479400_bib31","first-page":"319","article-title":"A progress report on the Medical Research Council's therapeutic trial in myelomatosis","volume":"15","author":"Galton","year":"1968","journal-title":"Br J Haematol"},{"key":"2023042013000479400_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.beha.2005.01.010","article-title":"Novel biological therapies for the treatment of multiple myeloma","volume":"18","author":"Richardson","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"2023042013000479400_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"2023042013000479400_bib34","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"2023042013000479400_bib35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.beha.2006.06.006","article-title":"Thalidomide and lenalidomide in multiple myeloma","volume":"19","author":"Mazumder","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"2023042013000479400_bib36","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"2023042013000479400_bib37","first-page":"1781","article-title":"New treatments for multiple myeloma","volume":"19","author":"Richardson","year":"2005","journal-title":"Oncology (Williston Park)"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/83\/978\/217\/50023163\/postgradmedj-83-217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/83\/978\/217\/50023163\/postgradmedj-83-217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:07:30Z","timestamp":1682003250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/83\/978\/217\/7045240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":37,"journal-issue":{"issue":"978","published-online":{"date-parts":[[2007,4,2]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2006.054627","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,4]]},"published":{"date-parts":[[2007,4,1]]}}}